First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours

The goal of this clinical trial is to learn if the OATD-02 administration (orally) in monotherapy is safe and has the pharmacodynamic potential to restore and enhance tumour responses to immunotherapy through increased arginine levels or intrinsic anti-tumour activity in participants with advanced metastatic colorectal cancer, ovarian cancer, renal cancer or pancreatic cancer.

Trial Details

NCT ID
NCT05759923
Phase
PHASE1
Sponsor
Molecure S.A.
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • OATD-02
Locations (sample)
  • Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland|53.1235,18.00762
  • Otwock, Masovian Voivodeship, Poland|52.10577,21.26129
  • Warsaw, Masovian Voivodeship, Poland|52.22977,21.01178

Key Eligibility Criteria

  • Capable of understanding and complying with protocol requirements.
  • Male or female patient aged ≥18 years at Screening.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Histologically or cytologically confirmed advanced and/or metastatic colorectal cancer, renal cell cancer, or pancreatic cancer or recurrent serous…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →